Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2003
03/06/2003WO2003017983A1 A new extended release oral dosage form
03/06/2003WO2003017979A1 Method for the production of inhalation powders
03/06/2003WO2003017974A1 Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
03/06/2003WO2003017973A1 A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
03/06/2003WO2003017971A1 Drug delivery system
03/06/2003WO2003017960A1 Oral rinse for treatment or prevention of bacterial and fungal infection
03/06/2003WO2003017946A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003WO2003017935A2 Human antibodies specific for interleukin 15 (il-15)
03/06/2003WO2003017932A2 Compositions and methods for targeting cerebral circulation and treatment of headache
03/06/2003WO2003017928A2 Method for treating bronchial constriction and bronchospam
03/06/2003WO2003017927A2 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003WO2002102381A9 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
03/06/2003WO2002100844A3 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
03/06/2003WO2002095036A8 A novel intein and uses thereof
03/06/2003WO2002094830A3 DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
03/06/2003WO2002092122A3 Use of osteopontin for the treatment and/or prevention of neurologic diseases
03/06/2003WO2002089794A8 Method for treating neuropathic pain and pharmaceutical preparation therefor
03/06/2003WO2002089780A3 Antiviral compounds
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002085446A3 Microprojection array immunization patch and method
03/06/2003WO2002083066A3 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
03/06/2003WO2002074249A3 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
03/06/2003WO2002064210A3 Combination therapy comprising anti-diabetic and anticonvulsant agents
03/06/2003WO2002064096A3 Methods of using pyrimidine-based antiviral agents
03/06/2003WO2002060501A3 Hydrogel wound dressing,preparation and use thereof
03/06/2003WO2002059302A3 Regulation of human serotonin-like g protein-coupled receptor
03/06/2003WO2002058692A9 Halogenated composition, method for preparing same and uses thereof
03/06/2003WO2002058681A8 Use of rhein for preparing a medicine for treating a high level of il-1
03/06/2003WO2002055106A3 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
03/06/2003WO2002051994A8 Polypeptides
03/06/2003WO2002049605A3 Methods and compositions for protecting and restoring skin using selective mmp inhibitors
03/06/2003WO2002043661B1 Recombinant anti-cd30 antibodies and uses thereof
03/06/2003WO2002043507A3 Nutrient supplements and methods for treating autism and for preventing the onset of autism
03/06/2003WO2002041837A3 Treatment of mucositis
03/06/2003WO2002031151A3 Lipocalins
03/06/2003WO2002028409A3 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
03/06/2003WO2002026947A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/06/2003WO2002022678A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/06/2003WO2002012325A3 Suppressor gene
03/06/2003WO2002009714A9 Compositions and methods for the treatment of anorectal disorders
03/06/2003WO2002005797A8 Use of dopamine d2/d3 receptor agonists to treat fibromyalgia
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003WO2001074900A9 Nuclear factor kb inducing factor
03/06/2003WO2001072781A9 Human genes and expression products
03/06/2003WO2001066741A9 Kcnb: a novel potassium channel protein
03/06/2003WO2001055393A9 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
03/06/2003US20030045902 Composite staple for completing an anastomosis
03/06/2003US20030045865 Compositions and techniques for localized therapy
03/06/2003US20030045829 Therapeutic agent delivery tampon
03/06/2003US20030045755 Polyamine analogues as cytotoxic agents
03/06/2003US20030045746 Phosphorous organic compounds and their use
03/06/2003US20030045585 Treatment of psoriasis
03/06/2003US20030045580 Making, by coating ibuprofen or its salt with hydroxypropylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose or gelatin as binder, in specified weight percents; dosage forms
03/06/2003US20030045579 Compounds and compositions for delivering active agents
03/06/2003US20030045576 Composition for pain mediation and apparatus and method of use thereof
03/06/2003US20030045567 (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003US20030045563 Comprises cyclooxygenase-2 inhibitors (celecoxib, rofecoxib); water solubility; vasodilation/headache relief; for inhibition of precipitation and/or crystallization in gastrointestinal fluids
03/06/2003US20030045553 Peroxisome proliferator-activated receptor agonists (PPAR) for increasing insulin sensitivity in treatment of diabetes and Syndrome X
03/06/2003US20030045534 Pharmaceutical combination of antiviral agents
03/06/2003US20030045529 Method for specifically potentiating N-type Ca2+ channel activity
03/06/2003US20030045524 Particularly quinoxaline, (2-imidozolin-2-ylamino) quinoxaline, or 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline and linolenic acid, which may be complexed with the quinoxaline agonist
03/06/2003US20030045521 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
03/06/2003US20030045519 Treating allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion)
03/06/2003US20030045515 Cyanoguanidine I kappa B kinase inhibitors as antiproliferative agents for cancer treatment
03/06/2003US20030045512 Androstanecarbothioic acid derivatives, especially esterified with thazol-5-ylcarboxylic acid; formulation for administration by inhalation
03/06/2003US20030045508 Phosphoramidates
03/06/2003US20030045505 Oligosaccharide having at least a D-galactose unit bound by an alpha (1-6) bond with a sucrose unit; second component is a molecule positively charged at physiological pH and that promotes pinocytosis or membrane penetration
03/06/2003US20030045501 Use of atazanavir in HIV therapy
03/06/2003US20030045494 Synthetic oligonucleotides complementary to nucleic acids encoding epidermal growth factor
03/06/2003US20030045475 Reducing the rate of islet cell infiltration by lymphocytes in a diabetes-susceptible mammal by administering a gonadotropin-releasing hormone antagonist.
03/06/2003US20030045470 Methods and compositions for modulating gluconeogenesis using PGC-1
03/06/2003US20030045466 Calcium binding protein
03/06/2003US20030045461 Composition and methods of esterified nitroxides gated with carboxylic acids
03/06/2003US20030045459 67 Human secreted proteins
03/06/2003US20030045458 Capable of directing supra-lethal doses of radiation, called Hot-Spots, virtually exclusively to the cancer.
03/06/2003US20030045449 Pharmaceutical combinations for the treatment of neurodegenerative diseases
03/06/2003US20030044975 Cytokine-binding domain for use in the treatment of asthma and thrombocytopenia
03/06/2003US20030044961 Compositions for transferring active compounds in a cell-specific manner
03/06/2003US20030044950 Phosphodiesterase 10
03/06/2003US20030044888 Polypeptide for use in the treatment of addison's disease
03/06/2003US20030044845 Novel therapeutic agents for membrane transporters
03/06/2003US20030044810 Methods, compositions, and kits relating to cardiovascular disease
03/06/2003US20030044809 Detection of preferential transcription factor; obtain library, screen with probe, detect hybridization, recover clone, monitor transcriptional activity of protein codes in cloned nucleotide sequences
03/06/2003US20030044783 Human genes and gene expression products
03/06/2003US20030044776 Detection of cell death modulators; obtain sample, induce cell death, monitor mitochondrial permeability, detect and evaluate adjustment
03/06/2003US20030044768 PD-1, a receptor for B7-4, and uses therefor
03/06/2003US20030044474 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
03/06/2003US20030044473 Blood type dietary supplements
03/06/2003US20030044468 Shaping polymeric precursors by inducing thermal gelation of an aqueous solution thereof and then curing said precursors by crosslinking reactive groups; biomedical uses include drug delivery, microencapsulation, implantation
03/06/2003US20030044458 Oral dosage form comprising a therapeutic agent and an adverse-effect agent
03/06/2003US20030044452 Composition for topical administration
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030044439 Treatment of skin with adenosine or adenosine analog
03/06/2003US20030044438 Adapted for improving skin ageing and/or photoageing signs, which cutaneous signs are directly a result of a chronic micro-inflammatory process induced by repeated UV exposures
03/06/2003US20030044403 Anti-infective therapy
03/06/2003US20030044390 Applying stresses to blood sampling
03/06/2003US20030044114 Source wavelength shifting apparatus and method for delivery of one or more selected emission wavelengths
03/06/2003US20030042202 Low molecular weight thrombin inhibitors
03/06/2003CA2496180A1 Nucleic acid and polypeptide linked to breast cancer and uses therefor
03/06/2003CA2468466A1 Use of pregnane-diones or diols as neuropathic analgesic agents
1 ... 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 ... 1151